Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
NCT05928390 · View on ClinicalTrials.gov ↗
Study Summary
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).
Conditions Studied
Interventions
- DRUG Pasireotide Diaspartate
Study Locations (20)
Other
- Universitaire Ziekenhuizen Leuven, Department of Gastroenterology and Hepatology,Herestraat 49 — Leuven
- AP-HP Hopital Europeen Georges Pompidou, 20, rue Leblanc, — Paris
- HCL Centre Hospitalier Lyon Sud — Pierre-Bénite
- Hopital Rangueil, Attachée de Recherche Clinique, Centre Investigation Clinique, CHU, Cedex 9, France — Toulouse
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola — Bologna
- Azienda Ospedale - Università Padova, Clinica Medica 3, Via Giustiniani, 2, — Padua
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone — Palermo
- Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, L.go Gemelli 8 — Rome
- Hospital Universitario Vall d'Hebron, Passeig Vall d´Hebron 119-129, Spain — Barcelona
- Hospital Clinic Barcelona, Lipid Clinic End, Nutr. Service Hospital Clinic, C. Villarroel, 170, — Barcelona
California
- Stanford University School of Medicine, Endocrinology, 800 Welch Road, — Palo Alto
Illinois
- Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago
Louisiana
- NOLA Care — Metairie
Maryland
- Velocity Clinical Research - Annapolis — Annapolis
Massachusetts
- Joslin Diabetes CenterJoslin Diabetes Center, One Joslin Place — Boston
Minnesota
- Mayo Clinic - Rochester, 200 First Street, SW, 55905 — Rochester
New York
- Montefiore Medical Center, 111 E 210th Street, — The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2024-01-04 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05928390
The ClinicalTrials.gov registry entry for NCT05928390 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RECORDATI GROUP, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Post-Bariatric Hypoglycemia appearing as the primary indexed condition, and to 1 intervention — of which Pasireotide Diaspartate is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05928390 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Other, California, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05928390 about?
NCT05928390 is a clinical study titled "Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia". The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatme...
What is the current status of trial NCT05928390?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2024-01-04. Estimated completion is 2026-04.
What conditions does trial NCT05928390 study?
This clinical trial studies the following conditions: Post-Bariatric Hypoglycemia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05928390?
The interventions under investigation include: Pasireotide Diaspartate (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05928390?
This trial is sponsored by RECORDATI GROUP, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05928390 being conducted?
This trial has 20 study locations across California, Illinois, Louisiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.